Injectable lipolytics and complications from their use

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. There are a lot of non-certified products on the cosmetology market, and there is no tendency to reduce the share of such low-quality drugs at the moment. It is important to be able to correctly diagnose and treat patients with complications after injectable lipolytic therapy with non-certified drugs. The article discusses the terminology, experience of injectable lipolysis, classification of lipolytics, the mechanism of action of phosphatidylcholine and deoxycholic acid, indications and contraindications for their use, topography of the method of injectable lipolysis, an overview of the most widely used lipolytics, their side reactions and complications. Description of the clinical case. A description of a clinical case of the development of an inflammatory reaction after injectable lipolytic therapy (non-certified in the Russian Federation) with an analysis of the tactics of correction the complication is given. This clinical case demonstrates the importance of using certified products. The objective reasons for the development of complications, in addition to the poor quality of the injected drug, may be inadequate injection technique (too close location of individual injections and their insufficient depth), the introduction of a large volume of lipolytic mixture, as well as non-compliance with the asepic and antiseptic regulations.

Full Text

Restricted Access

About the authors

Evgenia V. Ikonnikova

Central State Medical Academy of the Administrative Department of the President of the Russian Federation; Institute of Plastic Surgery and Cosmetology

Email: evikonnikova@bk.ru
Associate Professor, Department of Dermatovenereology and Cosmetology

N. E Manturova

Institute of Plastic Surgery and Cosmetology; Pirogov Russian National Research Medical University

L. S Kruglova

Central State Medical Academy of the Administrative Department of the President of the Russian Federation

A. L Rodina

Central State Medical Academy of the Administrative Department of the President of the Russian Federation

References

  1. Duncan D.I., Palmer M. Fat reduction using phosphatidylcholine/sodium deoxycholate injections: standard of practice. Aesthetic Plast Surg. 2008;32:858-72. doi: 10.1007/s00266-008-9188-9.
  2. Ширшакова М.А. Мезотерапевтическая коррекция эдематозно-фиброзной панникулопа-тии (целлюлита) и локальных жировых отложений. ПХиК. 2010;3:445-49.
  3. Ширшакова М.А. Мезотерапия целлюлита: некоторые практические рекомендации. Инъекционные методы в косметологии. 2011;2:26-9
  4. Rotunda A.M., Kolodney M.S. Mesotherapy and phosphatidylcholine injections: historical clarification and review. Dermatol Surg. 2006;32(4):465-80. doi: 10.1111/j.1524-4725.2006.32100.
  5. Lijnen FI, Echevaria-Vazquez D., Petrov V. Influence of cholesterol-lowering on plasma membrane lipids and function. Methods Find. Exp Clin Pharmacol. 1996;18:123-36.
  6. Lieber C.S., Robins S.J., Li J., et al. Phosphatidylcholine protects against fibrosis and cirrhosis in the baboon. Gastroenterol. 1994;106:152-59. doi: 10.1016/s0016- 5085(94)95023-7.
  7. Little A., Levy R., Chuaqui-Kidd P, Hand D. A double-blind, placebo-controlled trial of high-dose lecithin in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1985;48:736-42. doi: 10.1136/jnnp.48.8.736.
  8. Cohen B.M., Lipinski J.F., Altesman R.l. Lecithin in the treatment of mania: double-blind, placebo-controlled trials. Am J.Psychiatry. 1982;139:1162-64. doi: 10.1176/ajp.139.9.1162.
  9. Bobkova V.I., Lokshina L.I., Korsunskii V.N., Tananova G.V. Metabolic effect of lipostabil-forte. Kardiol. 1989;29:57-60.
  10. Rittes P.G., Rites C. Treatment of aging neck with Lipostabil Endovena. J. Drugs Dermatol. 2009;8:937-39.
  11. Heinrich K.G. Efficacy of injections of phosphatidylcholine into fat deposits - A non-surgical alternative to liposuction in body-contouring. Indian J Plast Surg. 2005;38(2):119-22 doi: 10.4103/0970-0358.19779.
  12. Hexsel D., Serra M., Mazzuco R., et al. Phosphatidylcholine in the treatment of localized fat. J Drugs Dermatol. 2003;2:511-18.
  13. Rittes PG. The lipodissolve technique: clinical experience. Clin Plast Surg. 2009;36:215-21. doi: 10.1016/j.cps.2008.11.003.
  14. Hasengschwandtner F. Injection lipolysis for effective reduction of localized fat in place of minor surgical lipoplasty. Aesthet Surg J. 2006;26:125 doi: 10.1016/j.asj.2006.01.008.
  15. Peckitt N. Evidence based practice: phosphatidylcholine. A review of evidence for the mode of action in injection lipolysis. Jeremy Mills Publishing: Yorkshire, UK. 2005. 154 p.
  16. Duncan D, Rotunda A.M. Injectable therapies for localized fat loss: state of the art. Clin Plast Surg. 2011;38:489-501. Doi: 10.1016/j. cps.2011.02.005.
  17. Rotunda A.M., Suzuki H., Moy R.L., Kolodney M.S. Detergent effects of sodium deoxycholate are a major feature of an injectable phosphatidylcholine formulation used for localized fat dissolution. Dermatol Surg. 2004;30:1001-8. doi: 10.1111/j.1524-4725.2004.30305.
  18. Hasengschwandtner F. Phosphatidylcholine treatment to induce lipolysis. J Cosmet Dermatol. 2005;4:308-13. doi: 10.1111/j.1473-2165.2005.00211.
  19. Rose PT, Morgan M. Histological changes associated with mesotherapy for fat dissolution. J Cosmet Laser Ther. 2005;7:17-9. doi: 10.1080/14764170510037743.
  20. Palumbo P, Melchiorre E., La Torre C., et al. Effects of phosphatidylcholine and sodium deoxycholate on human primary adipocytes and fresh human adipose tissue.Int J Immunopathol Pharmacol. 2010;23:481-89. doi: 10.1177/039463201002300210.
  21. Duncan D., Rubin J.P, Golitz L., et al. Refinement of technique in injection lipolysis based on scientific studies and clinical evaluation. Clin Plast Surg. 2009;36:195-209. Doi: 10.1016/j. cps.2008.11.001.
  22. Salti G., Ghersetich I., Tantussi F., et al. Phosphatidylcholine and sodium deoxycholate in the treatment of localized fat: a double-blind, randomized study. Dermatol Surg. 2008;34:60-6; discussion 66. doi: 10.1111/j.1524-4725.2007.34009.
  23. Rotunda A.M., Ablon G., Kolodney M.S. Lipomas treated with subcutaneous deoxycholate injections. J Am Acad Dermatol. 2005;3:973-78. doi: 10.1016/j.jaad.2005.07.068.
  24. Yagima Odo M.E., Cuce L.C., Odo L.M., Natrielli A. Action of sodium deoxycholate on subcutaneous human tissue: local and systemic effects. Dermatol Surg. 2007;33:178-88; discussion 88-9. doi: 10.1111/j.1524-4725.2006.33036.
  25. American Society for Aesthetic Plastic Surgery. National plastic surgery statistics: Cosmetic and reconstruction procedure trends. New York: American Society for Aesthetic Plastic Surgery. URL: http://www.plasticsurgery.org/public_education/statistical_trends.cf.
  26. Vedamurthy M. Mesotherapy. Indian J Dermatol Venereol Leprol. 2007;73:60-2. doi: 10.4103/0378-6323.30661.
  27. Gupta A., Lobocki C., Singh S., et al. Actions and comparative efficacy of phosphatidylcholine formulation and isolated sodium deoxycholate for different cell types. Aesthet Plast Surg. 2009;33:346-52. doi: 10.1007/s00266-008-9301-0.
  28. Duncan D., Hasengschwandtner F. Lipodissolve for subcutaneous fat reduction and skin retraction. Aesthet Surg J. 2005;25(5):530-43. doi: 10.1016/j.asj.2005.07.009.
  29. Gowelli H.M., Sabaa B., Yosry E., Saghir H. Histopathological and ultra-structural characterization of local neuromuscular damage induced by repeated phosphatidylcholine/ deoxycholate injection. Exp Toxicol Pathol. 2016;68(1):39-46. Doi: 10.1016/j. etp.2015.09.006.
  30. Blandford A.D., Ansari W., Young J.M., et al. Deoxycholic acid and the marginal mandibular nerve: a cadaver study. Aesthet Plast Surg. 2018;42(5):1394-98. doi: 10.1007/s00266-018-1164-4.
  31. Sorenson E., Chesnut C. Marginal mandibular versus pseudo-marginal mandibular nerve injury with submandibular deoxycholic acid injection. Dermatol Surg. 2018;44(5):733-35. doi: 10.1097/DSS.0000000000001291.
  32. Fagien S., Mcchesney P., Subramanian M., et al. Prevention and management of injection-related adverse effects in facial aesthetics: considerations for ATX-101 (deoxycholic acid injection) treatment. Dermatol Surg. 2016;42(1):300-4. doi: 10.1097/DSS.0000000000000898.
  33. Jones D.H., Carruthers J., Joseph J.H., et al. REFINE-1, a multicenter, randomized, doubleblind, placebo-controlled, phase 3 trial with ATX-101, an injectable drug for submental fat reduction. Dermatol Surg. 2016;42(1):38-49. doi: 10.1097/DSS.0000000000000578.
  34. Souyoul S., Gioe O., Emerson A., Hoope D. Alopecia after injection of ATX-101 for reduction of submental fat. Case Rep. JAAD Case Rep. 2017;3(3):250-52. Doi: 10.1016/j. jdcr.2017.02.021.
  35. Metzger K.C., Crowley E.L., Kadlubowska D., et al. Uncommon adverse effects of deoxycholic acid injection for submental fullness: beyond the clinical trials. J Cutan Med Surg. 2020;24(6):619-24. doi: 10.1177/1203475420943270.
  36. Prantl L., Gehmert S., Brebant V., et al. Lipolytic effects of nano particle sized polyenylphosphatidylcholine on adipose tissue: first promising in vitro and in vivo results. Hoesl Lin Hemorheol Microcirc. 2020;75(2):189-99. doi: 10.3233/CH-190715.
  37. Urbani C.E. Urticarial reaction to ethylenediamine in aminophylline following mesotherapy. Contact Dermat. 1994;31:198-99. doi: 10.1111/j.1600-0536.1994.tb01975.x
  38. Vikbjerg A.F., Mu H., Xu X. Lipase-catalyzed acyl exchange of soybean phosphatidylcholine in n-Hexane: a critical evaluation of both acyl incorporation and product recovery. Biotechnol Prog. 2005; 21(2):397-404. Doi: 10.1021/ bp049633y.
  39. Duncan D.I., Chubaty R. Clinical safety data and standards of practice for injection lipolysis: a retrospective study. Aesthet Surg J. 2006;26:575-85. doi: 10.1016/j.asj.2006.08.006.
  40. Rosina P, Chieregalo C., Miccolis D., D Onghia F.S. Psoriasis and side-effects of mesotherapy.Int J Dermatol. 2001;40:581-83. doi: 10.1046/j.1365-4362.2001.01248-3.x
  41. Gokdemir G., Kucukunal A , Sakiz D. Cutaneous granulomatous reaction from mesotherapy. Dermatol Surg. 2009;35:291-93. doi: 10.1111/j.1524-4725.2008.01053.x
  42. Davis M.D., Wright T.I., Shehan J.M. A complication of mesotherapy: noninfectious granulomatous panniculitis. Arch Dermatol. 2008;144:808-9. doi: 10.1001/archderm.144.6.808
  43. Tan J., Rao B. Mesotherapy-induced panniculitis treated with dapsone: case report and review of reported adverse effects of mesotherapy.J Cutan Med Surg. 2006;10:92-5. doi: 10.2310/7750.2006.00013.
  44. Kutlubay Z., Gokalp H., Ince U., Engin B. Cutaneous foreign body granulomas associated with lipolytic cocktail: Who is the enemy, mesotherapy or drugs injected? J Cosmet Laser Ther. 2017;19(5):310-12. doi: 10.1080/14764172.2017.1303167

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies